Stavudine(D4T, ZERIT™) sensitivities in clinical HIV isolates obtained from a pediatric population. Cynthia R Jackson 1,3 Cindy 1, Vayro 3


Journal Article

Stavudine (D4T. ZERIT™) is a nucteoside analog reverse transcriptase (RT) inhibitor of HIV RT that is approved for use in children and adults with symptomatic HIV infection unresponsive to prior therapy. We determined the pre-treatment 1C50 (concentration of drug that inhibits 50% viral replication) for D4T in both a treatment naive and treatment experienced group of HIV positive children. IC50, were also determined after D4T monotherapy was initiated in the treatment experienced group. A peripheral blood mononuclear cell (PBMC) based anti-retroviral resistance assay was performed for determination of D4T 1C50 on 89 clinical isolates. The clinical isolates were obtained from HIV positive children followed by the Duke University Pediatrie Infectious Disease Clinic. Twenty-nine clinical isolates obtained from eleven patients with no history of prior anti-retroviral therapy were used to determine mean 1C50 for D4T. The clinical isolates were obtained from time points varying from 1 to 27 months prior to starting therapy with D4T. Six of the eleven patients had more than one clinical isolate available for calculation of 1C50,. The mean 1C50 for D4T in patients prior to anti-retroviral therapy was 1.06μM ±1.21 Twenty-seven isolates from five patients who had been on previous nucleoside analogs were available for PBMC assay and 1C50 calculation. Clinical isolates from the five patients represented time points from 1-55 months prior to starting D4T therapy. The mean 1C50 for the treatment experienced group was 1.68 ±1.54μM. Thirty-three isolates representing six patients who had received previous nudeoside analog therapy were available for PBMC assay after D4T monotherapy was instituted. The mean value was 2.30 ±1.91μM. No significant difference (students t-test. p=0.10) was noted between the pre-D4T 1C50 in the treatment naive and treatment experienced groups of HIV positive children. The pretreatment DAT IC50 in the treatment experienced group was not significantly different from post-treatment values (t-test, p=0 2). Previous nudeoside analog therapy did not seem to alter D4T 1C50, in pédiatrie patients currenfly receiving DAT monotherapy.

Duke Authors

Cited Authors

  • Diliberti, JH; Valentins, ME; McKinney, RE; St Clair, MH

Published Date

  • December 1, 1996

Published In

Volume / Issue

  • 7 / 4

Start / End Page

  • 283 -

International Standard Serial Number (ISSN)

  • 1045-5418

Citation Source

  • Scopus